null

null

null

null

Pre-revenue clinical-stage biotech; minimal debt, primarily equity-financed; cash runway ~12-18 months as of last filing; 20% rate rise immaterial to debt service

Negligible direct interest expense; sensitivity manifests through higher discount rates compressing DCF valuations and tightening biotech equity capital markets

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API synthesis reagents from China-based chemical suppliers; 2) specialized oncology trial sites concentrated in US/EU with CRO dependency

Minimal international revenue; clinical-stage company with US-centric operations; sovereign currency devaluation exposure effectively null at current stage

Primarily US-based operations; clinical trials conducted domestically; no material international revenue markets generating currency devaluation exposure

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

CRO partners (e.g., ICON, Covance) represent non-substitutable near-term operational inputs; switching mid-trial would cause 12-24 month delays and significant cost

Clinical-stage biopharmaceutical; revenue model is milestone/partnership-based, not SaaS; cloud disruption risk is low but affects internal R&D data pipelines

Potential licensing and co-development partnerships with large pharma; no secondary commercial revenue stream currently active

API coupling risk low; primary data systems are internal genomics/bioinformatics pipelines; proprietary ecDNA targeting platform creates high scientific switching cost

Low Howey risk; equity shares in a regulated biotech do not constitute investment contracts beyond standard securities law; no token or crypto element

Very High

Moderate HIPAA exposure from clinical trial patient data; limited GDPR/CCPA risk given minimal EU consumer data collection; clinical data governance is primary concern

Negligible; pre-commercial stage with no market share; ecDNA oncology niche is nascent and uncontested; no pricing or market dominance concerns

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Effectively 0% recurring commercial revenue; 100% dependent on non-dilutive grants, collaboration milestones, and equity raises; no product revenue yet

Future monetization via oncology drug approval and royalties/licensing; current vector is partnership milestone payments from potential pharma collaborators

No commercial pricing architecture yet; future oncology drug pricing likely $100K-$300K/year per patient based on comparable targeted therapies; payer reimbursement is key risk

Potentially high if ecDNA-targeting therapies achieve breakthrough designation; orphan oncology drugs command premium pricing with limited payer pushback historically

Targeted gross margin 80-90% post-commercialization typical for biotech small-molecule/biologic; current stage shows negative operating margins

No commercial product; free-rider leakage not applicable; clinical trial dropout rate is the operational analog, typically 10-20% in oncology trials

Headcount-linear at current R&D stage; doubling pipeline programs requires proportional scientific/clinical staff; no scalable platform leverage until commercialization

Marginal cost of advancing each additional drug candidate is high (~$50-100M per IND-to-Phase II); not sublinear; each program requires dedicated resources

Not applicable; no franchise network; FDA IND/NDA regulatory compliance is the analog risk, with significant CMC and GCP audit exposure

At 10x scale (post-approval), CAC analog is physician/KOL education cost; rare oncology drugs typically require 50-100 targeted oncologist relationships per indication

No meaningful network effects; scientific publication and clinical data credibility create reputational compounding but not true network effects

AI displacement risk moderate; ecDNA target identification could be accelerated by AI, but wet-lab validation and clinical execution remain human/capital intensive

Low recession resistance; clinical-stage biotech dependent on equity capital markets, which contract sharply in recessions; patient demand for oncology drugs is inelastic

Large pharmaceutical/biotech partners (potential licensing); extreme concentration risk — one or two partnership deals could represent 100% of non-equity revenue

Government/NIH grant funding as secondary non-dilutive capital source; NCI and CPRIT grants have historically supported ecDNA research

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated to future-state R&D infrastructure (genomics, CRISPR screening); no legacy operations to reallocate from; burn is entirely forward-looking pipeline investment

0001782303

BOLD